October 17, 2017
Speaker: Jane F. Barlow
Real Endpoints LLC
Implications for bempedoic acid?
• Creating and delivering on payer expectations is key
• Payers will welcome an option that is lower cost than PCSK9 inhibitors
• There remains a sizeable number of patients that can’t get to goal with statins and ezetimibe
• Payers’ feedback on the profiles of the combination and bempedoic acid:
‒ On-going cardiovascular outcomes trials – potential limitation
‒ New mechanism of action – positive
‒ LDL-C lowering ability and safety profile – positive
‒ Oral route of administration; less complexity – positive
‒ Combination drug (bempedoic acid + ezetimibe) – positive
view event >
April 29, 2018 - May 2, 2018
Table 10| The Palazzo| Las Vegas, NV
Speaker and Host: Roger Longman
Attendee: Real Endpoints Team
Asembia’s Annual Specialty Pharmacy Summit will return to Wynn & Encore Las Vegas from April 29 through May 2, 2018. The Summit welcomes thousands of industry executives and professionals. Agenda highlights include business workshops, educational seminars, exhibits, and live continuing education credits, along with numerous networking and social events.
April 24, 2018
Boston, MA
Panelist: Michael Sherman, Chief Medical Officer, Harvard Pilgrim
Panelist: C. Bernie Good, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, UPMC
Moderator: Roger Longman, CEO, Real Endpoints
(Invitation only)
March 21, 2018
New York, NY
Keynote Speaker: Roger Longman
Real Endpoints LLC
The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers.
February 27, 2018 - February 28, 2018
Philadelphia, PA
Attendee: Real Endpoints Team
Over 700 leaders in Patient Access, Brand Management, Reimbursement and Specialty Distribution across the industry have benefited from CBI’s Hub and SPP Model Optimization conference series.
January 17, 2018 3pm EST
Webinar
Speaker: Dan Danielson, Pharmacy Manager, Premera BlueCross
Speaker: Dan Olendorf, Chief Scientific Officer, Institute for Clinical & Economic Review (ICER)
Moderator: Jane Barlow, EVP & Chief Clinical Officer, Real Endpoints
Adventures in over-, under-, and correctly estimating drug costs…and defining what’s worth the extra money.
November 14, 2017
New York, NY
Panelist : Norman Shelby
Real Endpoints LLC
Immuno-oncology treatments have provided renewed hope to cancer patients. Combination treatments bring the promise of increased efficacy with manageable side effects.
Manager
Payer & Channel Insights, Marketing Analytics & Business Insights